MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation — Stella

Recruiting

Back to Kidney Transplant; Complications trials

Trial locations(1 site)

Italy

University of Rome Tor Vergata, Rome

Key details

Sponsor

University of Rome Tor Vergata

Enrollment target

~300 participants

Started

December 2022

Primary completion

May 2026

Age range

18 Years – 70 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov